In addition to EGFR gene copy numbers, Cappuzzo et al (2005c) reported that increased HER2 gene copy number is associated with response to gefitinib therapy in EGFR-mutated NSCLC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.